肿瘤细胞治疗研究
英文原题：The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
几种靶向CD19的CAR-T 细胞（CART19）产品已被批准用于治疗复发/难治性非霍奇金淋巴瘤（NHL）和急性淋巴细胞白血病（ALL）患者。
靶向CD19的CAR-T 细胞（CART19）产品已有数种获批用于治疗复发/难治性非霍奇金淋巴瘤（NHL）和急性淋巴细胞白血病（ALL）患者。尽管缓解率非常令人瞩目，但仍有相当比例的患者出现疾病复发并死于疾病进展。CART19治疗失败的一个主要原因是肿瘤细胞中CD19表达的丢失或下调，这促使了大量旨在靶向一种以上抗原（例如CD19和CD20或CD22）的新型策略的出现。双靶向可以通过联合输注两种独立产品、用两种不同载体共转导、双顺反子盒或串联受体来实现。在本文中，我们综述了每种策略的优缺点以及迄今为止获得的临床结果。
Several products containing chimeric antigen receptor T cells targeting CD19 (CART19) have been approved for the treatment of patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) and acute lymphoblastic leukaemia (ALL). Despite very impressive response rates, a significant percentage of patients experience disease relapse and die of progressive disease. A major cause of CART19 failure is loss or downregulation of CD19 expression in tumour cells, which has prompted a myriad of novel strategies aimed at targeting more than one antigen (e.g. CD19 and CD20 or CD22). Dual targeting can the accomplished through co-administration of two separate products, co-transduction with two different vectors, bicistronic cassettes or tandem receptors. In this manuscript, we review the pros and cons of each strategy and the clinical results obtained so far.
MEMBER ACCOUNT
登录成功会直接打开下一页。
